Core Viewpoint - China Zhongfu (01763.HK) anticipates a decline in revenue and net profit for the fiscal year ending December 31, 2025, compared to the same period in 2024, primarily due to decreased earnings from its nuclear medical equipment division and tax-related expenses from a subsidiary [1] Financial Performance - Revenue is expected to be approximately RMB 6.979 billion to RMB 7.206 billion, representing a year-on-year decrease of about 5% to 8% [1] - Net profit is projected to be around RMB 611 million to RMB 655 million, reflecting a year-on-year decline of approximately 25% to 30% [1] - Profit attributable to equity shareholders is estimated to be between RMB 302 million and RMB 322 million, indicating a year-on-year reduction of about 20% to 25% [1] Operational Status - The company's operations are currently normal, despite the anticipated revenue and profit declines [1] - The decrease in revenue for the fiscal year 2025 is mainly attributed to a downturn in the nuclear medical equipment segment [1] - The profit reduction is significantly influenced by tax payments and penalties from the subsidiary Shenzhen Zhonghe Haidewei Biotechnology Co., Ltd. [1]
中国同辐(01763.HK)：预计2025年度净利润6.11亿元至6.55亿元 同比减少约25...